1. Home
  2. Companies
  3. CMB
  4. Announcements

Cambium Bio (ASX:CMB)

ASX announcement history & article coverage

5
Total announcements
(in last 3 months)
2
With article
3
No article
Article coverage
40%
Transparent by design. Announcments by Cambium Bio (ASX:CMB) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.

24 June 2026 · 12:12 pm AEST ASX Filing
Becoming a substantial holder
Becoming a substantial holder
24 June 2026 · 10:28 am AEST ASX Filing
Change in substantial holding - ZYBT
Change in substantial holding
16 June 2026 · 10:43 am AEST ASX Filing
Becoming a substantial holder
Becoming a substantial holder

28 Apr 2026 · 09:10 am AEST ⚡ Price SensitiveMaterial ASX Filing
Quarterly Activities/Appendix 4C Cash Flow Report
Cambium Bio advances Phase 3 readiness with FDA single-trial pathway confirmation and A$2.4M strategic placement
Commitments Test Entity - Third Quarter Activity ReportCommitments Test Entity - Third Quarter Cashflow Report
85
Cambium Bio Secures FDA Nod for Single-Trial Phase 3 and Raises A$2.4M from Major Shareholder Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026 Wrap
23 Apr 2026 · 01:01 pm AEST ⚡ Price SensitiveMaterial ASX Filing
FDA Confirms Single Pivotal Trial Pathway for Elate Ocular
FDA Approves Single-Trial Pathway for Cambium Bio's Elate Ocular, Cutting Costs and Accelerating Approval
Progress Report
90
FDA Greenlights Single Pivotal Trial for Cambium Bio’s Elate Ocular, Slashing Costs and Timelines Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026 Wrap Market Wrap - Week 17 (20 Apr -> 24 Apr) 2026 Wrap